Vrionis F D
Department of Neurosurgery, Tufts University School of Medicine and New England Medical Center, Boston, Massachusetts 02111, USA.
J Neurooncol. 1998 Jun-Jul;38(2-3):241-4. doi: 10.1023/a:1005900807890.
Gene therapy of neoplastic meningosis is a promising new approach that relies on introduction of 'suicide' genes into cancer cells. The most commonly used gene has been the herpes virus thymidine kinase gene (HSV-tk) which has been delivered to cancer cells via retroviral or adenoviral vectors. A bystander cytocidal effect to non-transduced tumor cells has been documented and is dependent upon intercellular communication via gap junctions. A variety of gene therapy approaches using the HSV-tk system have been used in experimental models of neoplastic meningosis with promising results. Optimizing vector design and bystander cytotoxicity is a prerequisite for successful gene therapy in patients with neoplastic meningosis.
肿瘤性脑膜炎的基因治疗是一种很有前景的新方法,它依赖于将“自杀”基因导入癌细胞。最常用的基因是疱疹病毒胸苷激酶基因(HSV-tk),该基因已通过逆转录病毒或腺病毒载体传递到癌细胞中。已证明对未转导的肿瘤细胞存在旁观者杀细胞效应,且这种效应依赖于通过间隙连接的细胞间通讯。在肿瘤性脑膜炎的实验模型中,已经使用了多种使用HSV-tk系统的基因治疗方法,并取得了有希望的结果。优化载体设计和旁观者细胞毒性是肿瘤性脑膜炎患者基因治疗成功的先决条件。